I don’t know about toclizumab specifically, but “biologicals” (monoclonals that attack certain phases of the immune response, hence the -mab suffix) are expensive and produced in low volumes as Rx for rare diseases.
With regard to COVID, this agent would be useful for end-stage cytokine storm, and probably not otherwise.
Ya, it was sort of a rhetorical question.
I guess if you get to the point that you’ve got to have it, you gotta have it.
Let’s just hope not too many people gotta have it.